Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects
Aditi Sinha, Arvind Bagga(All India Institute of Medical Sciences), Prachi Tewari(All India Institute of Medical Sciences), Sree Laya Kalluru(All India Institute of Medical Sciences), Srinivasavaradan Govindarajan(All India Institute of Medical Sciences), Georgie Mathew(Christian Medical College, Vellore), Angeli Misra, Megha Brijwal(All India Institute of Medical Sciences), Pankaj Hari(Indian Council of Medical Research), Arushi Arushi(All India Institute of Medical Sciences), Kshetrimayum Ghanapriya(All India Institute of Medical Sciences), Priyanka Khandelwal(Chacha Nehru Bal Chikitsalaya), Neetu Grewal(All India Institute of Medical Sciences), Khushboo Rai(All India Institute of Medical Sciences)
Cited by 32
Related Papers
Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome
|Journal of the American Society of Nephrology|2004|415
Clinical Features of Anti-Factor H Autoantibody–Associated Hemolytic Uremic Syndrome
|Journal of the American Society of Nephrology|2010|296
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|256
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
|Kidney International|2013|216
Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome
|Clinical Journal of the American Society of Nephrology|2010|203